AI assistant
Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2024
May 14, 2024
31324_rns_2024-05-14_86ebd9c9-8a45-4075-bd75-80038fc5f3d5.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name
TELIX PHARMACEUTICALS LIMITED
Date of this announcement
Wednesday May 15, 2024
The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred
| Total number of | |||
|---|---|---|---|
| ASX +security | +securities to be | ||
| code | Security description | issued/transferred | Issue date |
| TLXAP | SHARE RIGHTS | 35,000 | 13/05/2024 |
| TLXAO | SHARE APPRECIATION RIGHTS | 3,095,526 | 13/05/2024 |
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of entity
TELIX PHARMACEUTICALS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
1.2 Registered number type Registration number ACN 616620369
1.3 ASX issuer code
TLX
1.4 The announcement is
New announcement
1.5 Date of this announcement
15/5/2024
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description
TLXAP : SHARE RIGHTS
Date the +securities the subject of this notification were issued 13/5/2024
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes
| Were any of the +securities issued to +key management personnel (KMP) or | an +associate? |
|---|---|
| Yes | |
| Provide details of the KMP or +associates being issued +securities. | |
| Name of KMP Name of registered holder |
Number of +securities |
| Richard Valeix Richard Valeix |
35,000 |
| Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme | |
| or a summary of the terms Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at nancial-reports-presentations/ |
https://telixpharma.com/investor-centre/fi |
| Any other information the entity wishes to provide about the +securities the | subject of this notification |
| The second tranche of Performance Share Rights (exercise price: nil) granted to | Richard Valeix (CCO) as part of his sign |
| on to the CCO role as detailed in section 5.4.1 of the 2023 Remuneration report. | Vesting is subject to achievement of the |
| performance conditions of the 2024 Long Term Variable Remuneration (LTVR). |
Issue details
Number of +securities
35,000
ASX +security code and description
TLXAO : SHARE APPRECIATION RIGHTS
Date the +securities the subject of this notification were issued
13/5/2024
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes
Provide details of the KMP or +associates being issued +securities.
| Provide details of the KMP | or +associates being issued +securities. | |
|---|---|---|
| Name of KMP | Name of registered holder | Number of +securities |
| Darren Smith | Darren Smith | 50,874 |
| Richard Valeix | Richard Valeix | 60,358 |
| David Cade | David Cade | 49,461 |
| Darren Patti | Darren Patti | 66,838 |
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at https://telixpharma.com/investor-centre/fi nancial-reports-presentations/
Any other information the entity wishes to provide about the +securities the subject of this notification
Performance Share Appreciation Rights (PSARs) (exercise price: $11.94) granted to Telix employees as 2024 Long Term Variable Remuneration (LTVR) as part of Total Target Remuneration Package for 2024. This includes Long Term Incentive PSARs granted to Darren Patti in relation to his role prior to being appointed as Group Chief Operating Officer. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2024-2026. For further details refer to the Remuneration report in Telix's 2023 Annual Report accessible at https://telixpharma.com/investor-centre/financial-reports-presentations/
Issue details
Number of +securities
3,095,526
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
5 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| Total number of | |
|---|---|
| ASX +security code and description | +securities on issue |
| TLX : ORDINARY FULLY PAID | 330,455,778 |
| 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) | |
| Total number of | |
| ASX +security code and description | +securities on issue |
| TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL | 80,000 |
| TLXAR : PERFORMANCE RIGHTS | 2,523,720 |
| TLXAP : SHARE RIGHTS | 1,230,000 |
| TLXAO : SHARE APPRECIATION RIGHTS | 11,212,780 |
| TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37 | 584,492 |
| TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL | 100,000 |
| TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38 | 685,510 |
| TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS | 440,000 |
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
6 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
7 / 7